Spun off from Abbott Laboratories in January 2013 with a single product generating 63 per cent of revenue, AbbVie was supposed to collapse when that product lost patent protection. Instead, the company replaced more than $20 billion in HUMIRA erosion and posted a record $61.2 billion in 2025.
When AbbVie became an independent company on 1 January 2013, it had 21,000 employees and one product that mattered. HUMIRA, the adalimumab biologic for autoimmune diseases, generated roughly 63 per cent of total revenue. No major pharmaceutical company in modern history had been so dependent on a single molecule. The concentration was not a secret. Analysts wrote about it. Competitors planned for it. Everyone in the industry understood the arithmetic: when HUMIRA lost exclusivity, AbbVie would face a revenue cliff that no amount of cost-cutting could offset.
The numbers made the vulnerability concrete. In 2014, AbbVie’s first full year as a public company, total revenue was $19.1 billion. HUMIRA alone would reach $14 billion by 2015, growing 22 per cent year over year and accounting for more of the company’s sales than many entire pharmaceutical companies generate in total. By 2016, the drug contributed roughly $16 billion of AbbVie’s $25.6 billion in revenue. The question was never whether HUMIRA would lose patent protection. It was whether AbbVie could build enough replacement revenue before it did.
What followed was not a pivot driven by panic. AbbVie had twelve years of advance warning. The company used every one of them. It built an internal pipeline, acquired an entire portfolio through the largest deal in its history, and launched two immunology drugs that would eventually generate billions in combined revenue. The dependency that was supposed to destroy AbbVie instead forced a discipline that most pharmaceutical companies never develop: the ability to plan a transition a decade before it becomes necessary, and then execute it.
In June 2019, AbbVie announced it would acquire Allergan plc for $63 billion. The reaction on Wall Street was scepticism verging on hostility. AbbVie’s share price dropped. Analysts questioned the logic of paying a premium for a company whose flagship aesthetic product, Botox, had no obvious connection to immunology or oncology. The deal looked like a company buying diversification at any price because it had no other options.
The critics were wrong, though it took two years for the arithmetic to prove it. The Allergan acquisition, completed in May 2020, gave AbbVie three things it could not have built organically in the time available. First, Botox: not just the aesthetic franchise but the therapeutic applications in migraine and overactive bladder that generated billions in revenue independent of beauty trends. Second, an eye care portfolio anchored by Restasis and the pipeline that would produce new treatments for dry eye disease. Third, a neuroscience business including Vraylar, a treatment for bipolar disorder and schizophrenia that would become one of AbbVie’s fastest-growing products.
The combined company reported $45.8 billion in revenue for 2020, its first year together, with 47,000 employees. That was more than double AbbVie’s revenue at its 2013 spinoff. The Allergan deal was the most expensive diversification play in pharmaceutical history. It was also, measured by what happened next, one of the most consequential. When HUMIRA’s US exclusivity finally ended in January 2023, AbbVie had the revenue base to absorb the blow. Without Allergan, it is difficult to see how the company could have survived what came next.
HUMIRA’s US exclusivity ended in January 2023. The biosimilars arrived. Revenue from the drug, which had peaked at roughly $21 billion globally, began its expected decline. For any other company, this would have been a catastrophe. For AbbVie, it was the event the entire organization had spent a decade preparing for.
The replacement strategy rested on two molecules that had been in development since AbbVie was still part of Abbott. Skyrizi (risankizumab), an IL-23 inhibitor for psoriasis and psoriatic arthritis, and Rinvoq (upadacitinib), a JAK inhibitor for rheumatoid arthritis and atopic dermatitis, were both launched before the HUMIRA cliff arrived. By 2023, Skyrizi and Rinvoq generated a combined $11.7 billion in revenue. They were not just replacements for HUMIRA. They were, in several indications, better drugs: more targeted mechanisms, less frequent dosing, and efficacy data that physicians increasingly preferred.
The 2023 results told the story. Total revenue was $54.3 billion, down from the $58 billion peak in 2022 as HUMIRA eroded. But the decline was contained. The neuroscience portfolio, bolstered by Vraylar and Qulipta for migraine, contributed $7.7 billion. Botox continued to grow. And the immunology franchise, even net of HUMIRA losses, held. By 2024, revenue recovered to $56.3 billion. By 2025, AbbVie posted $61.2 billion, a new all-time record, with 57,000 employees. The company had replaced more than $20 billion in HUMIRA erosion and come out larger on the other side. In the history of pharmaceutical patent cliffs, no company has managed a transition of this magnitude.
The twelve-year revenue arc tells you everything about what AbbVie built. In 2014, the company generated $19.1 billion with 26,000 employees. By 2016, revenue had grown to $25.6 billion, driven almost entirely by HUMIRA’s continued expansion into new autoimmune indications. By 2018, AbbVie crossed $32.7 billion. The growth was real, but it was fragile: one drug was still doing most of the work.
The Allergan acquisition in 2020 broke that pattern. Revenue jumped to $45.8 billion as the combined entity reported its first full year. It reached $56 billion in 2021, $58 billion in 2022. Then came the HUMIRA cliff, the dip to $54.3 billion in 2023, and the recovery. The 2025 figure of $61.2 billion represents a more than threefold increase from the 2014 starting point. The employee count grew from 21,000 at the spinoff to 57,000, reflecting both organic growth and the Allergan workforce.
Over the decade, AbbVie invested more than $55 billion in research and development. That figure is not an abstraction. It produced Skyrizi and Rinvoq, which together are on track to exceed $27 billion in combined annual revenue by 2027 according to AbbVie’s own guidance. It funded the neuroscience pipeline that gave the company Vraylar and Qulipta. And it maintained the HUMIRA franchise long enough for the replacement products to reach commercial scale. The R&D spend was not a cost. It was the mechanism by which a one-drug company became a diversified pharmaceutical enterprise generating revenue across immunology, oncology, neuroscience, aesthetics, and eye care.
Sources: AbbVie Annual Reports (10-K) 2014–2025. AbbVie 10-Year Impact Report. OPPI member directory.